Pfizer's Norvasc
Executive Summary
"Approvable" as of April 22. Pfizer is seeking approval for the once-a-day calcium channel blocker (amlodipine) in the treatment of angina and hypertension. Norvasc was recommended for approval in June 1991 by FDA's Cardiovascular and Renal Drugs Advisory Committee, which voted seven to zero on the hypertension indication but split on the drug's angina data ("The Pink Sheet" June 10, 1991, p. 3).